Common use of EXPERTS Clause in Contracts

EXPERTS. The consolidated financial statements of Augmedix, Inc. appearing in Augmedix, Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 have been audited by Xxxxx, Xxxxxxxx + Co. LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC a registration statement on Form S-3 under the Securities Act, of which this prospectus supplement forms a part. The rules and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For further information about us and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. We file reports, proxy statements and other information with the SEC under the Exchange Act. The SEC maintains an Internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is xxx.xxx.xxx.

EXPERTS. The consolidated financial statements as of Augmedix, Inc. appearing in Augmedix, Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 2019 and 2018 and for the years then ended incorporated by reference in this prospectus supplement have been audited so incorporated by Xxxxxreference in reliance on the reports of Xxxxxxxx & Company, Xxxxxxxx + Co. LLP, our independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such said firm as experts in accounting auditing and auditingaccounting. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC a registration statement on Form S-3 under the Securities Actfile annual, of which this prospectus supplement forms a part. The rules quarterly and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For further information about us and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. We file current reports, proxy statements and other information with the SEC under the Exchange ActSEC. The SEC maintains an Internet internet website that contains reports, proxy statements and information statements, and other information about issuers, like us, regarding issuers that file electronically with the SEC, including the Company at xxx.xxx.xxx. You may also access our SEC reports and proxy statements free of charge at our website, xxx.xxxxxxxxxxxxxxx.xxx. The address of information contained in, or that can be accessed through, our website is xxx.xxx.xxxnot part of this prospectus supplement. This prospectus supplement and the accompanying prospectus are part of the registration statement on Form S-3 filed with the SEC under the Securities Act for the Common Stock offered by this prospectus supplement. This prospectus supplement does not contain all of the information set forth in the registration statement, certain parts of which have been omitted in accordance with the rules and regulations of the SEC. For further information, reference is made to the registration statement and its exhibits. Whenever we make references in this prospectus supplement or the accompanying prospectus to any of our contracts, agreements or other documents, the references are not necessarily complete and you should refer to the exhibits attached to the registration statement for the copies of the actual contract, agreement or other document.

EXPERTS. The consolidated financial statements of AugmedixPacific Ethanol as of and for the years ended December 31, Inc. 2019 and 2018 appearing in Augmedix, Inc.Pacific Ethanol’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 2019 have been audited by Xxxxx, Xxxxxxxx + Co. RSM US LLP, an independent registered public accounting firm, as set forth stated in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. WHERE YOU CAN FIND MORE ADDITIONAL INFORMATION We have filed with the SEC a registration statement on Form S-3 under the Securities Act, of which this prospectus supplement forms a part. The and the rules and regulations promulgated under the Securities Act, with respect to the securities offered under this prospectus. This prospectus, which constitutes a part of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For further , does not contain all of the information about us and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to contained in the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. Many of the contracts and documents described in this prospectus are filed as exhibits to the registration statements and you may review the full text of these contracts and documents by referring to these exhibits. For further information with respect to us and the securities offered under this prospectus, reference is made to the registration statement and its exhibits and schedules. We file reports, proxy statements including annual reports on Form 10-K, quarterly reports on Form 10-Q and other information current reports on Form 8-K with the SEC under the Exchange ActSEC. The SEC maintains an Internet website web site that contains reports, proxy and information statements and other information about regarding issuers, like usincluding Pacific Ethanol, that file electronically with the SEC. The SEC’s Internet website address is xxxx://xxx.xxx.xxx. Our Internet website address is xxx.xxxxxxxxxxxxxx.xxx. We do not anticipate that we will send an annual report to our stockholders until and unless we are required to do so by the rules of that website is xxx.xxx.xxxthe SEC. All trademarks or trade names referred to in this prospectus are the property of their respective owners.

EXPERTS. The financial statements incorporated by reference into this prospectus have been so included in reliance on the report of Xxxxxx LLP, related to the consolidated financial statements of Augmedix, Inc. appearing in Augmedix, Inc.’s Annual Report on Form 10-K for the fiscal year years ended December 31June 30, 2021 have been audited by Xxxxx2019 and 2018, Xxxxxxxx + Co. LLP, an independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such said firm as experts in accounting auditing and auditingaccounting. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC Commission a registration statement on Form S-3 under the Securities Act, of which Act for the common stock in this offering. This prospectus supplement forms a part. The rules and regulations does not contain all of the SEC allow us to omit from this prospectus supplement information in the registration statement and the accompanying prospectus certain information included in exhibits and schedule that were filed with the registration statement. For further information about with respect to us and the securities our common stock, we are offering under this prospectus supplement and the accompanying prospectus, refer you should refer to the registration statement and the exhibits and schedules that were filed with the registration statement. With respect to the statements Statements contained in this prospectus supplement and the accompanying prospectus regarding about the contents of any agreement contract or any other documentdocument that is filed as an exhibit to the registration statement are not necessarily complete, in each instance, and we refer you to the statement is qualified in all respects by the complete full text of the agreement contract or document, a copy of which has been other document filed as an exhibit to the registration statement. We file reportsannual, proxy statements quarterly, and current reports and other information with the SEC under Commission. Our filings with the Exchange ActCommission are available to the public on the Commission’s website at xxx.xxx.xxx. Those filings are also available to the public on our corporate website xxxxx.xxxxxxx.xxx. The SEC maintains an Internet information we file with the Commission or contained on, or linked to through, our corporate website or any other website that contains reportswe may maintain is not part of this prospectus or the registration statement of which this prospectus is a part. You may also read and copy, proxy statements and other information about issuersat the Commission’s prescribed rates, like us, that any document we file electronically with the SECCommission, including the registration statement (and its exhibits) of which this prospectus is a part, at the Commission’s Public Reference Room located at 000 X Xxxxxx, X.X., Xxxxxxxxxx, X.X. 00000. The address You can call the Commission at 1-800- SEC-0330 to obtain information on the operation of that website is xxx.xxx.xxxthe Public Reference Room.

EXPERTS. The consolidated financial statements of Augmedix, Inc. appearing incorporated in Augmedix, Inc.this prospectus supplement by reference from the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 2020 have been audited by Xxxxx, Xxxxxxxx + Co. XXXXX LLP, an independent registered public accounting firm, as set forth stated in their report thereonreport, included therein, and which is incorporated herein by reference. Such consolidated financial statements are have been so incorporated herein by reference in reliance upon such the report given on the authority of such firm given upon their authority as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC a registration statement on Form S-3 under the Securities Actfile annual, of which this prospectus supplement forms a part. The rules quarterly and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For further information about us and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. We file current reports, proxy statements and other information with the SEC. Our SEC under filings are available over the Exchange ActInternet at the SEC’s website at xxx.xxx.xxx. The SEC maintains an Internet a website that contains reports, proxy and information statements and other information about issuers, like us, regarding issuers that file electronically with the SEC at xxxx://xxx.xxx.xxx. Our website address is xxx.xxxxxxxxx.xxx. The information contained on, or that can be accessed through, our website is not a part of this prospectus or incorporated by reference into this prospectus or any prospectus supplement. We have included our website address as an inactive textual reference only. This prospectus supplement is part of a registration statement we filed with the SEC. The address of This prospectus supplement and the accompanying prospectus omit some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our consolidated subsidiary and the securities we are offering. Statements in this prospectus supplement and in the accompanying prospectus concerning any document we filed as an exhibit to the registration statement or that website is xxx.xxx.xxxwe otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements.

EXPERTS. The consolidated financial statements as of AugmedixDecember 31, Inc. appearing 2021 and 2020 and for each of the three years in Augmedix, Inc.’s Annual Report on Form 10-K for the fiscal year period ended December 31, 2021 and management’s assessment of the effectiveness of internal control over financial reporting as of December 31, 2021 incorporated by reference in this prospectus and in the registration statement have been audited by Xxxxxso incorporated in reliance on the reports of BDO USA, Xxxxxxxx + Co. LLP, an independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such said firm as experts in accounting and auditing. WHERE YOU CAN FIND MORE ADDITIONAL INFORMATION We have filed with the SEC a registration statement on Form S-3 under the Securities Act, of which this prospectus supplement forms a part. The rules and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For further information about us and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. We file reports, proxy statements and other information with the SEC under the Exchange ActSEC. The SEC maintains an Internet a website that contains reports, proxy and information statements and other information about issuers, like such as us, that who file electronically with the SEC. The address of that website is xxx.xxx.xxx. Our website address is xxx.xxxxxxxxx.xxx. The information on our website, however, is not, and should not be deemed to be, a part of this prospectus. This prospectus is part of a registration statement that we filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Forms of the indenture and other documents establishing the terms of the offered securities are or may be filed as exhibits to the registration statement or documents incorporated by reference in the registration statement. Statements in this prospectus about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement through the SEC’s website, as provided above.

EXPERTS. The consolidated financial statements as of AugmedixDecember 31, Inc. appearing 2020 and 2019 and for each of the three years in Augmedix, Inc.’s Annual Report on Form 10-K for the fiscal year period ended December 31, 2021 2020 and management’s assessment of the effectiveness of internal control over financial reporting as of December 31, 2020 incorporated by reference in this prospectus supplement and in the Registration Statement have been audited by Xxxxxso incorporated in reliance on the reports of BDO USA, Xxxxxxxx + Co. LLP, an independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report , given on the authority of such said firm as experts in accounting auditing and auditingaccounting. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC a registration statement on Form S-3 under the Securities Act, of which this prospectus supplement forms a part. The rules and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For further information about us and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. We file reports, proxy statements and other information with the SEC under the Exchange Act. The SEC maintains an Internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is xxx.xxx.xxx.

EXPERTS. The consolidated financial statements of Augmedix, Inc. appearing incorporated in Augmedix, Inc.this prospectus supplement by reference from the Company’s Annual Report on Form 10-K for the fiscal year ended December 31K, 2021 have been audited by Xxxxx, Xxxxxxxx + Co. Deloitte & Touche LLP, an independent registered public accounting firm, as set forth stated in their report thereonreport, included therein, and which is incorporated herein by reference. Such consolidated financial statements are have been so incorporated herein by reference in reliance upon such the report given on the authority of such firm given upon their authority as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION We are a reporting company and file annual, quarterly and current reports, proxy statements and other information with the SEC. We have filed with the SEC a registration statement on Form S-3 under the Securities Act, of which this prospectus supplement forms a part. The rules and regulations of Act with respect to the SEC allow us to omit from securities being offered under this prospectus supplement and the accompanying prospectus. This prospectus certain supplement and the accompanying prospectus do not contain all of the information included set forth in the registration statement and the exhibits to the registration statement. For further information about with respect to us and the securities we are offering being offered under this prospectus supplement and the accompanying prospectus, we refer you should refer to the registration statement and the exhibits and schedules filed with as a part of the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. We file reports, proxy statements and other information with the SEC under the Exchange Act. The SEC maintains an Internet website site that contains reports, proxy statements and information statements, and other information about issuers, like us, regarding issuers that file electronically with the SEC, including Fulgent. The address SEC's Internet site can be found at xxxx://xxx.xxx.xxx. We maintain a website at xxx.xxxxxxxxxxxxxxx.xxx. Information contained in or accessible through our website does not constitute a part of that website is xxx.xxx.xxxthis prospectus supplement or the accompanying prospectus.

EXPERTS. The consolidated financial statements of AugmedixAlbireo Pharma, Inc. appearing in Augmedix, Inc.’s Annual Report on Form 10-K for the fiscal year ended at December 31, 2021 2016, and for the year then ended, incorporated by reference in this prospectus and the registration statement of which this prospectus forms a part have been audited by XxxxxXxxxx & Young LLP (United States), Xxxxxxxx + Co. LLPindependent registered public accounting firm, and at December 31, 2015, and for the year then ended, by Xxxxx & Young LLP (United Kingdom), independent registered public accounting firm, as set forth in their report thereon, included thereinrespective reports thereon incorporated by reference herein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference included in reliance upon such report reports given on the authority of such firm firms as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION We have filed with are subject to the SEC a registration statement on Form S-3 under the Securities Act, of which this prospectus supplement forms a part. The rules and regulations reporting requirements of the SEC allow us to omit from this prospectus supplement Exchange Act and the accompanying prospectus certain information included in the registration statement. For further information about us file annual, quarterly and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. We file current reports, proxy statements and other information with the SEC under the Exchange ActSEC. The SEC maintains an Internet website that contains You may read and copy these reports, proxy statements and other information at the SEC’s public reference facilities at 000 X Xxxxxx, X.X., Xxxx 0000, Xxxxxxxxxx, X.X. 00000. You can request copies of these documents by writing to the SEC and paying a fee for the copying cost. Please call the SEC at 0-000-XXX-0000 for more information about issuersthe operation of the public reference facilities. SEC filings are also available at the SEC’s web site at xxxx://xxx.xxx.xxx. This prospectus is only part of a registration statement on Form S-3 that we have filed with the SEC under the Securities Act of 1933, like usas amended, and therefore omits certain information contained in the registration statement. We have also filed exhibits and schedules with the registration statement that file electronically with are excluded from this prospectus, and you should refer to the applicable exhibit or schedule for a complete description of any statement referring to any contract or other document. You may inspect a copy of the registration statement, including the exhibits and schedules, without charge, at the public reference room or obtain a copy from the SEC upon payment of the fees prescribed by the SEC. We also maintain a website at xxx.xxxxxxxxxxxxx.xxx, through which you can access our SEC filings. The address of that information set forth on our website is xxx.xxx.xxxnot part of this prospectus.

EXPERTS. The consolidated financial statements of AugmedixVirgin Galactic Holdings, Inc. appearing as of December 31, 2021 and 2020, and for each of the years in Augmedix, Inc.’s Annual Report on Form 10the three-K for the fiscal year period ended December 31, 2021 2021, and management’s assessment of the effectiveness of internal control over financial reporting as of December 31, 2021, have been audited incorporated by Xxxxx, Xxxxxxxx + Co. reference herein in reliance upon the reports of KPMG LLP, independent registered public accounting firm, as set forth in their report thereon, included thereinincorporated by reference herein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such said firm as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION INFORMATION; INCORPORATION BY REFERENCE Available Information We have filed with the SEC a registration statement on Form S-3 under the Securities ActAct with respect to, among other securities, the shares of which common stock offered by this prospectus supplement forms a partand accompanying prospectus. The rules and regulations of the SEC allow us to omit from this This prospectus supplement and the accompanying prospectus certain do not contain all of the information included in the registration statement. For further information about pertaining to us and the securities our common stock we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statementits exhibits. With respect to the statements Statements contained in this prospectus supplement and the accompanying prospectus regarding the contents concerning any of any agreement our contracts, agreements or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement documents are not necessarily complete. If a contract or document, a copy of which document has been filed as an exhibit to the registration statement, we refer you to the copy of the contract or document that has been filed. Each statement in this prospectus supplement and the accompanying prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. We are subject to the informational requirements of the Exchange Act and file reportsannual, proxy statements quarterly and current reports and other information with the SEC. Our filings with the SEC under are available to the Exchange Actpublic on the SEC’s website at xxxx://xxx.xxx.xxx. The SEC maintains an Internet website that contains reports, proxy statements and other information about issuers, like us, that file You may access these materials free of charge as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. Those filings are also available to the public on, or accessible through, our website under the heading “Investor Information” at xxx.xxxxxxxxxxxxxx.xxx. The address information on our web site, however, is not, and should not be deemed to be, a part of that website is xxx.xxx.xxxthis prospectus supplement and accompanying prospectus.

EXPERTS. The consolidated Ernst & Young LLP, independent registered public accounting firm, has audited our financial statements of Augmedix, Inc. appearing included in Augmedix, Inc.’s our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 have been audited by Xxxxx2019 and the effectiveness of our internal control over financial reporting as of December 31, Xxxxxxxx + Co. LLP, independent registered public accounting firm2019, as set forth in their report thereonreports, included therein, which are incorporated by reference in this prospectus supplement and incorporated herein by referenceelsewhere in this registration statement. Such consolidated Our financial statements are incorporated herein by reference in reliance upon such report on Ernst & Young LLP’s reports, given on the their authority of such firm as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC a registration statement on Form S-3 under the Securities Act, of which this prospectus supplement forms a part. The rules and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For further information about us and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. We file reports, proxy statements and other information with the SEC under the Exchange Act. The SEC maintains an Internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is xxx.xxx.xxx.

EXPERTS. The consolidated financial statements as of Augmedix, Inc. appearing in Augmedix, Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 2019 and 2018 and for the years then incorporated by reference in this prospectus and in the registration statement have been audited by Xxxxxso incorporated in reliance on the report of BDO USA, Xxxxxxxx + Co. LLP, an independent registered public accounting firmfirm (the report on the consolidated financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern), as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report , given on the authority of such said firm as experts in accounting auditing and auditingaccounting. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC a registration statement on Form S-3 with the SEC under the Securities Act, Act of which this 1933. This prospectus supplement forms a part. The rules and regulations is part of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For further information about us and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with but the registration statement. With respect to the statements contained in this prospectus supplement statement includes and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects incorporates by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statementreference additional information and exhibits. We file annual, quarterly and current reports, proxy statements and other information with the SEC under the Exchange ActSEC. The SEC maintains an Internet website a web site that contains reports, proxy and information statements and other information about issuersregarding companies, like ussuch as ours, that file documents electronically with the SEC. The address of that site on the worldwide web is xxxx://xxx.xxx.xxx. The information on the SEC’s web site is not part of this prospectus, and any references to this web site or any other web site are inactive textual references only. The SEC permits us to “incorporate by reference” the information contained in documents we file with the SEC, which means that we can disclose important information to you by referring you to those documents rather than by including them in this prospectus. Information that is incorporated by reference is considered to be part of this prospectus and you should read it with the same care that you read this prospectus. Later information that we file with the SEC will automatically update and supersede the information that is either contained, or incorporated by reference, in this prospectus, and will be considered to be a part of this prospectus from the date those documents are filed. We have filed with the SEC, and incorporate by reference in this prospectus: • our Annual Report on Form 10-K and Form 10-K/A for the year ended December 31, 2019 (filed with the SEC on March 30, 2020 and April 29, 2020, respectively); • our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020 (filed with the SEC on May 14, 2020 and August 10, 2020, respectively); • our Current Reports on Form 8-K filed with the SEC on January 3, 2020, February 6, 2020, March 12, 2020, March 30, 2020, April 23, 2020, June 11, 2020, June 17, 2020, August 4, 2020, September 15, 2020, October 5, 2020, and October 6, 2020 (to the extent filed and not furnished); and • the description of our common stock contained in our Registration Statement on Form 10/A filed on July 16, 2001, and any amendment or report filed with the Commission for the purpose of updating the description. We also incorporate by reference all additional documents that we file with the SEC under the terms of Section 13(a), 13(c), 14 or 15(d) of the Exchange Act that are made after the initial filing date of the registration statement of which this prospectus is a part and the effectiveness of the registration statement, as well as between the date of this prospectus and the termination of any offering of securities offered by this prospectus (excluding any portions thereof furnished by the Registrant, including but not limited to information furnished under Item 2.02 and Item 7.01 and any exhibits relating to Item 2.02 or Item 7.01 furnished under Item 9.01 of Form 8-K and any certification required by 18 U.S.C. § 1350). Any statement contained in this Registration Statement or in a document incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement or in any subsequently filed document that is deemed to be incorporated by reference in this Registration Statement modifies or supersedes such statement. You may request a copy of any or all of the documents incorporated by reference but not delivered with this prospectus, at no cost, by writing or telephoning us at the following address and number: Plus Therapeutics, Inc., 0000 Xxxxxxxx Xxxx., Xxxxx 000, Xxxxxx, Xxxxx 00000, telephone (000) 000-0000. We will not, however, send exhibits to those documents, unless the exhibits are specifically incorporated by reference in those documents. We make available free of charge on our website is xxx.xxx.xxx.our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports, as soon as reasonably practicable after we electronically file or furnish such materials to the Securities and Exchange Commission, or SEC. You may obtain a free copy of these reports in the Investor Relations section of our website, xxx.xxxxxxxxxxxxxxxx.xxx. $5,040,000 Common Stock PROSPECTUS SUPPLEMENT

EXPERTS. The consolidated financial statements as of Augmedix, Inc. appearing in Augmedix, Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 2019 and 2018 and for the years then ended incorporated by reference in this prospectus supplement have been audited by Xxxxxso incorporated in reliance on the report of BDO USA, Xxxxxxxx + Co. LLP, an independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report , given on the authority of such said firm as experts in accounting auditing and auditingaccounting. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC a registration statement on Form S-3 under the Securities Act, of which this prospectus supplement forms a partAct with respect to the securities being offered hereby. The rules and regulations of the SEC allow us to omit from this This prospectus supplement and the accompanying prospectus certain prospectus, which constitute a part of the registration statement, do not contain all of the information included set forth in the registration statementstatement or the exhibits and schedules filed therewith. For further information about us and the securities offered hereby, we are offering under this prospectus supplement and the accompanying prospectus, refer you should refer to the registration statement and the exhibits and schedules filed with the registration statementthereto. With respect to the statements Statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement contract or any other documentdocument that is filed as an exhibit to the registration statement are not necessarily complete, in and each instance, the such statement is qualified in all respects by reference to the complete full text of the agreement such contract or document, a copy of which has been other document filed as an exhibit to the registration statement. We file annual, quarterly and current reports, proxy statements and other information with the SEC under the Exchange ActSEC. The SEC maintains an Internet website site that contains reports, proxy statements and information statements, and other information about issuers, like us, regarding issuers that file electronically with the SEC, including us. The address SEC’s Internet site can be found at xxxx://xxx.xxx.xxx. In addition, we make available on or through our Internet site copies of these reports as soon as reasonably practicable after we electronically file or furnished them to the SEC. Our Internet site can be found at xxxx://xxx.xxxxxxxxxxxxxxx.xxx. The information contained in, or that can be accessed through, our website is xxx.xxx.xxxnot incorporated by reference in, and is not part of, this prospectus supplement or the accompanying prospectus.

EXPERTS. The Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements of Augmedix, Inc. appearing included in Augmedix, Inc.’s our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 have been audited by Xxxxx2021, Xxxxxxxx + Co. LLPand the effectiveness of our internal control over financial reporting as of December 31, independent registered public accounting firm2021, as set forth in their report thereonreports, included therein, which are incorporated by reference in this prospectus and incorporated herein by referenceelsewhere in the registration statement. Such consolidated Our financial statements are incorporated herein by reference in reliance upon such report on Ernst & Young LLP’s reports, given on the their authority of such firm as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC a registration statement on Form S-3 under the Securities Act, of which this prospectus supplement forms a part. The rules and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For further information about us and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statementstatement or otherwise filed with the SEC. We file reports, proxy statements and other information with the SEC under the Exchange Act. You may read and copy this information from the Public Reference Room of the SEC, 000 X Xxxxxx, X.X., Xxxx 0000, Xxxxxxxxxx, X.X. 00000, at prescribed rates. You may obtain information on the operation of the Public Reference Room by calling the SEC at 0-000-XXX-0000. The SEC also maintains an Internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is xxx.xxx.xxx.

EXPERTS. The consolidated financial statements of Augmedix, Inc. appearing incorporated in Augmedix, Inc.this prospectus by reference from the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 have been audited by Xxxxx, Xxxxxxxx + Co. Deloitte & Touche LLP, an independent registered public accounting firm, as set forth stated in their report thereonreport, included therein, and which is incorporated herein by reference. Such consolidated financial statements are have been so incorporated herein by reference in reliance upon such the report given on the authority of such firm given upon their authority as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC This prospectus is part of a registration statement on Form S-3 we filed with the SEC under the Securities Act, of which this prospectus supplement forms a part. The rules Act and regulations of does not contain all the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference therein. For further information about with respect to us and the securities common stock we are offering under this prospectus supplement and the accompanying prospectus, we refer you should refer to the registration statement and the exhibits and schedules filed with as a part of the registration statement. With respect Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the statements contained offer is not permitted. You should not assume that the information in this prospectus supplement and the accompanying prospectus regarding the contents is accurate as of any agreement date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any other document, in each instance, the statement is qualified in all respects by the complete text sale of the agreement or document, a copy of which has been filed as an exhibit to the registration statementcommon stock offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC under the Exchange ActSEC. The SEC maintains an Internet website that contains reports, proxy statements You may read and other information about issuers, like us, that copy any document we file electronically with the SEC at the SEC’s public reference room at 000 X Xxxxxx, X.X., Xxxxxxxxxx, X.X., 00000. The address Please call the SEC at 0.000.XXX.0000 for further information on the operation of that the public reference room. Our SEC filings are also available to the public at the SEC’s website is xxx.xxx.xxxat xxxx://xxx.xxx.xxx.

EXPERTS. The consolidated financial statements of AugmedixMoleculin Biotech, Inc. appearing in Augmedix, Inc.’s Annual Report on Form 10-K for the fiscal year ended as of December 31, 2021 2015 and for the period from July 28, 2015 (inception) to December 31, 2015 incorporated by reference in this prospectus have been audited by XxxxxGBH CPAs, Xxxxxxxx + Co. LLPPC, an independent registered public accounting firm, as set forth stated in their report thereon, included appearing therein, and incorporated herein by reference. Such consolidated financial statements are have been so included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. The audited financial statements of Moleculin Biotech, Inc. as of December 31, 2016 and for the year then ended incorporated herein by reference in this prospectus and elsewhere in the registration statement have been incorporated by reference in reliance upon such the report given on of Xxxxx Xxxxxxxx LLP, independent registered public accountants, upon the authority of such said firm as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION We have filed with This prospectus supplement and the SEC accompanying prospectus are part of a registration statement on Form S-3 we filed with the SEC under the Securities Act, of which this prospectus supplement forms a part. The rules Act and regulations of do not contain all the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included set forth or incorporated by reference in the registration statement. For further information about us and the securities we are offering under Whenever a reference is made in this prospectus supplement and or the accompanying prospectusprospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement and or the exhibits and schedules filed with the registration statement. With respect to the statements contained in reports or other documents incorporated by reference into this prospectus supplement and or the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, for a copy of which has been filed as an exhibit such contract, agreement or other document. Because we are subject to the registration statement. We information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy information filed by us with the SEC under at the Exchange ActSEC’s public reference section, 000 X Xxxxxx, X.X., Xxxxxxxxxx, X.X. 00000. Information regarding the operation of the public reference section can be obtained by calling 0-000-XXX-0000. The SEC also maintains an Internet website site at xxxx://xxx.xxx.xxx that contains reports, proxy statements and other information about issuers, like such as us, that who file electronically with the SEC. The address SEC allows us to “incorporate by reference” into this prospectus supplement the information in other documents that we file with it. This means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus supplement, and information in documents that website is xxx.xxx.xxx.we file later with the SEC will automatically update and supersede information contained in documents filed earlier with the SEC or contained in this prospectus supplement. We incorporate by reference in this prospectus supplement the documents listed below and any future filings that we may make with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination of the offering under this prospectus supplement; provided, however, that we are not incorporating, in each case, any documents or information deemed to have been furnished and not filed in accordance with SEC rules: • Our Annual Report on Form 10-K for the year ended December 31, 2016 (filed on April 3, 2017); • Our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2017 (filed on May 12, 2017) and June 30, 2017 (filed on August 11, 2017); • Our Current Reports on Form 8-K filed on February 9, 2017; February 23, 2017; March 14, 2017; March 22, 2017; April 17, 2017; May 19, 2017; May 31, 2017; June 27, 2017; June 30, 2017; July 12, 2017; July 27, 2017; August 25, 2017; and September 15, 2017; • Definitive Proxy Statement on Schedule 14A relating to the Company’s 2017 Annual Meeting of Stockholders (filed on April 28, 2017); and • the description of our common stock, par value $0.001 per share contained in our Registration Statement on Form 8-A, dated and filed with the SEC on April 28, 2016, and any amendment or report filed with the SEC for the purpose of updating the description. All reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering, including all such documents we may file with the SEC after the date of this prospectus supplement and accompanying prospectus, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus supplement and deemed to be part of this prospectus supplement from the date of the filing of such reports and documents. You may obtain a copy of any or all of the documents referred to above, which may have been or may be incorporated by reference into this prospectus supplement, including exhibits, at no cost to you by writing or telephoning us at the following address: Attention: Corporate Secretary, 0000 Xxxx Xxxxxxxx, Xxxxx 000, Xxxxxxx, Xxxxx 00000, telephone (000) 000-0000. S-8 PROSPECTUS $75,000,000 Moleculin Biotech, Inc.

EXPERTS. The Our consolidated financial statements as of AugmedixDecember 31, Inc. appearing 2019 and 2018 and for the years then ended incorporated in Augmedix, Inc.’s this prospectus by reference to the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 have been audited by XxxxxXxxxxxx & Xxxx, Xxxxxxxx + Co. LLPP.A., an independent registered public accounting firm, as set forth stated in their its report thereon, included thereinappearing in the registration statement, and are so incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such the report given on the authority of such firm given upon its authority as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION We have filed with are subject to the SEC a registration statement on Form S-3 under informational requirements of the Securities Exchange Act, of which this prospectus supplement forms a part. The rules and regulations of the SEC allow us to omit from this prospectus supplement in accordance therewith file annual, quarterly and the accompanying prospectus certain information included in the registration statement. For further information about us and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. We file current reports, proxy statements and other information with the SEC under the Exchange ActSEC. The SEC maintains an Internet internet website at xxx.xxx.xxx that contains periodic and current reports, proxy and information statements and other information about issuers, like us, regarding registrants that file are filed electronically with the SEC. These documents are also available, free of charge, through the Investors section of our website, which is located at xxx.xxxxxx.xxx. We have filed with the SEC a registration statement under the Securities Act of 1933, as amended, relating to the offering of these securities. The address registration statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus does not contain all of that website is the information set forth in the registration statement. You can obtain a copy of the registration statement for free at xxx.xxx.xxx. The registration statement and the documents referred to below under “Incorporation of Documents by Reference” are also available on our website, xxx.xxxxxx.xxx. We have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part of this prospectus.

EXPERTS. The Our consolidated financial statements balance sheets as of Augmedix, Inc. appearing in Augmedix, Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 2019 and 2018, and the related consolidated statements of operations, stockholders’ equity and cash flows for each of those two years have been audited by Xxxxx, Xxxxxxxx + Co. LLP, an independent registered public accounting firm, as set forth in their its report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC a registration statement on Form S-3 under the Securities Act, of which this prospectus supplement forms a part. The rules and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For further information about us and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. We file reports, proxy statements and other information with the SEC under the Exchange ActSEC. The SEC maintains an Internet website a web site that contains reports, proxy and information statements and other information about issuers, like such as us, that who file electronically with the SEC. The address of that website is xxx.xxx.xxxxxxx://xxx.xxx.xxx. Our website address is xxxxx://xxx.xxxxxxxxxxxxx.xxx. The information on our website, however, is not, and should not be deemed to be, a part of this prospectus. This prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Forms of the documents establishing the terms of the offered securities are or may be filed as exhibits to the registration statement. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement at the SEC’s Public Reference Room in Washington, D.C. or through the SEC’s website, as provided above.

EXPERTS. The consolidated financial statements balance sheets of AugmedixInhibikase Therapeutics, Inc. appearing in Augmedix, Inc.’s Annual Report on Form 10-K for the fiscal year ended as of December 31, 2021 and 2020, and the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows for each of the years then ended, have been audited by Xxxxx, Xxxxxxxx + Co. CohnReznick LLP, independent registered public accounting firm, as set forth stated in their report thereon, included therein, and which is incorporated herein by reference. Such consolidated financial statements are have been incorporated herein by reference in reliance upon such report given on the authority report of such firm given upon their authority as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC a registration statement on Form S-3 (File No. 333-262551) under the Securities Act, of which this prospectus supplement forms a part. The rules and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For further information about us and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. We file reports, proxy statements and other information with the SEC under the Exchange Act. The SEC maintains an Internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is xxx.xxx.xxx.

EXPERTS. The consolidated financial statements of Augmedixstatements, Inc. appearing in Augmedix, Inc.incorporated by reference from the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 2015, have been audited by Xxxxx, Xxxxxxxx + Co. Whitley Penn LLP, an independent registered public accounting firm, as set forth stated in their report thereonreport, included therein, and which is incorporated herein by reference. Such consolidated financial statements are have been so incorporated herein by reference in reliance upon such the report given on the authority of such firm given upon their authority as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC a registration statement on Form S-3 under the Securities Act, of which this prospectus supplement forms a part. The rules and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For further information about us and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. INFORMATION; INCORPORATION BY REFERENCE We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy information filed by us with the SEC under at the Exchange ActSEC’s public reference section, 000 X Xxxxxx, X.X., Xxxxxxxxxx, X.X. 00000. Information regarding the operation of the public reference section can be obtained by calling 0-000-XXX-0000. The SEC also maintains an Internet website site at xxxx://xxx.xxx.xxx that contains reports, proxy statements and other information about issuers, like such as us, that who file electronically with the SEC. We maintain an Internet site at xxx.xxxxxxxxxxxxxxxxxx.xxx. However, the information on our Internet sites is not incorporated by reference in this prospectus supplement and the accompanying prospectus and you should not consider it a part of this prospectus supplement or the accompanying prospectus. The SEC allows us to “incorporate by reference” into this prospectus supplement the information in other documents that we file with it. This means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus supplement, and information in documents that we file later with the SEC will automatically update and supersede information contained in documents filed earlier with the SEC or contained in this prospectus supplement. We incorporate by reference in this prospectus supplement the documents listed below and any future filings that we may make with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination of the offering under this prospectus supplement; provided, however, that we are not incorporating, in each case, any documents or information deemed to have been furnished and not filed in accordance with SEC rules: • Our Annual Report on Form 10-K for the year ended December 31, 2015 (filed on March 30, 2016); • Our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2016 (filed on May 16, 2016) and June 30, 2016 (filed on August 15, 2016); • Our Current Reports on Form 8-K filed on May 17, 2016, August 9, 2016, August 16, 2016 and August 26, 2016; • Definitive Proxy Statement on Schedule 14A relating to the Company’s 2016 Annual Meeting of Shareholders (filed on April 6, 2016); and • the description of our common stock, par value $0.01 per share contained in our Registration Statement on Form 8-A, dated and filed with the SEC on November 4, 2014, and any amendment or report filed with the SEC for the purpose of updating the description. All reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering, including all such documents we may file with the SEC after the date of the initial registration statement, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus supplement and deemed to be part of this prospectus supplement from the date of the filing of such reports and documents. You may obtain a copy of any or all of the documents referred to above which may have been or may be incorporated by reference into this prospectus supplement, except for exhibits to those documents (unless the exhibits are specifically incorporated by reference into those documents) at no cost to you by writing or telephoning us at the following address: Investor Relations, Abeona Therapeutics Inc., 0000 Xxx Xxxxxxx, Suite 600, Dallas, Texas 75219, telephone (000) 000-0000. S-9 PROSPECTUS $225,000,000 ABEONA THERAPEUTICS INC. Common Stock Preferred Stock Warrants Debt Securities We may offer or sell to the public from time to time in one or more series or issuances: • shares of our common stock; • shares of preferred stock; • warrants to purchase shares of our common stock, preferred stock and/or debt securities; • debt securities consisting of debentures, notes or other evidences of indebtedness; or • any combination of these securities. This prospectus provides a general description of the securities that we may offer. Each time that securities are sold under this prospectus, we will provide specific terms of the securities offered in a supplement to this prospectus. The prospectus supplement may also add, update or change information contained in this prospectus. This prospectus may not be used to consummate a sale of securities unless accompanied by the applicable prospectus supplement. You should read both this prospectus and the applicable prospectus supplement together with additional information described under the heading “Where You Can Find More Information” before you make your investment decision. Securities sold under this prospectus shall be sold directly to purchasers or through agents on our behalf or through underwriters or dealers as designated from time to time. If any agents or underwriters are involved in the sale of any of these securities, the applicable prospectus supplement will provide the names of the agents or underwriters and any applicable fees, commissions or discounts. Our common stock is listed on The NASDAQ Capital Market under the symbol “PTBI.” Beginning on June 22, 2015, our common stock will be listed on The NASDAQ Capital Market under the symbol “ABEO”, reflecting the change in our name from PlasmaTech Biopharmaceuticals, Inc. to Abeona Therapeutics Inc., as discussed elsewhere in this prospectus. On June 18, 2015, the closing price of our common stock was $6.53. As of June 18, 2015, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $96,389,000, based on 29,859,015 shares of outstanding common stock, of which approximately 14,760,908 shares are held by non- affiliates, and a per share price of $6.53 based on the closing sale price of our common stock on June 18, 2015. As of the date hereof, we have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof. In addition to the securities covered under this prospectus, our securities are currently also subject to ongoing public distribution pursuant to a prospectus covering the resale of an aggregate of 1,925,000 shares of our common stock issued to certain selling stockholders (pursuant to the registration statement on Form S-3, Registration No.333-204179). The mailing address of our principal executive offices is 0000 Xxx Xxxxxxx, Suite 600, Dallas, Texas 75219. Our telephone number is (000) 000-0000. Investing in our securities involves certain risks. Before investing, you should refer to the risk factors on page 11 of this prospectus, included in our periodic reports, in prospectus supplements and in other information filed by us with the Securities and Exchange Commission. This prospectus may not be used to offer or sell any securities unless accompanied by a prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. We may sell these securities on a continuous or delayed basis directly, through agents, dealers or underwriters as designated from time to time, or through a combination of these methods. We reserve the sole right to accept, and together with any agents, dealers and underwriters, reserve the right to reject, in whole or in part, any proposed purchase of securities. If any agents, dealers or underwriters are involved in the sale of any securities, the applicable prospectus supplement will set forth any applicable commissions or discounts. Our net proceeds from the sale of securities also will be set forth in the applicable prospectus supplement. The date of this prospectus is July 23, 2015. TABLE OF CONTENTS Prospectus Page About This Prospectus 5 Risk Factors 11 The Company 5 Use of Proceeds 34 Cautionary Note Regarding Forward-Looking Statements 34 Plan of Distribution 34 Ratio of Earnings to Combined Fixed Charges and Preferred Share Dividends Description of Our Common Stock 37 General Description of Securities That We May Sell 37 Description of Our Warrants 40 Description of Our Preferred Stock 39 Where You Can Find More Information; Incorporation by Reference 46 Description of Our Debt Securities 42 Experts 47 Legal Matters 47 ABOUT THIS PROSPECTUS This prospectus is part of a “shelf” registration statement. Under this process, we may sell, at any time and from time to time, in one or more offerings, any combination of the securities described in this prospectus. The exhibits to our Registration Statement contain the full text of certain contracts and other important documents we have summarized in this prospectus. Since these summaries may not contain all the information that you may find important in deciding whether to purchase the securities we offer, you should review the full text of these documents. The Registration Statement and the exhibits can be obtained from the Securities and Exchange Commission (“SEC”) as indicated under the heading “Where You Can Find More Information.” This prospectus only provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement that contains specific information about the terms of those securities and the terms of that offering. The prospectus supplement may also add, update or change information contained in this prospectus. You should read both this prospectus and any prospectus supplement together with the additional information described below under the heading “Where You Can Find More Information.” We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus and any accompanying prospectus supplement. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or an accompanying prospectus supplement. This prospectus and the accompanying prospectus supplement, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and the accompanying prospectus supplement, if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus and the accompanying prospectus supplement, if any, is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any accompanying prospectus supplement is delivered or securities are sold on a later date. References in this prospectus to the terms “the Company,” “Abeona,” “we,” “our” and “us” or other similar terms mean Abeona Therapeutics Inc., unless we state otherwise or the context indicates otherwise. THE COMPANY Overview Abeona Therapeutics Inc. (“Abeona” or the “Company”) is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeoxx’x lead program is a gene therapy for Xxxxxxxxxx syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Xxxxxxxxxx types A and B are anticipated to begin in 2015. The Company recently licensed a third gene therapy program in juvenile Xxxxxx disease from University of Nebraska Medical Center. In addition, the Company is pursuing two additional proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), and is active in the development and commercialization of human plasma-derived therapeutics, including its proprietary alpha-1 protease inhibitor, SDF Alpha™. Our principal executive office is located at 0000 Xxx Xxxxxxx, Suite 600, Dallas, Texas 75129. Our website is xxx.xxx.xxxaddresses are xxx.xxxxxxxxxxxxxxxxxx.xxx and xxx.xxxxxxxxxxxxx.xxx. We do not incorporate by reference into this prospectus the information on our website, and you should not consider it as part of this prospectus.